A Phase 2 interventional study of ALD518 and 0.9% saline in Oral Mucositis, sponsored by CSL Behring. Terminated at 31 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.
Among the 80 studies in Stomatitis with a site in United States, this one is the 30th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2011, is one of 33 in phase 2, and was the 29th registered.
306 studies on the registry are indexed under Stomatitis; 75 are open to participants now.
Browse Stomatitis studies →12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:
UNCANCER LLC · Sites in United States
Ages 18+
Baptist Health South Florida · Sites in United States
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
Woman's · Sites in United States
Ages 18+
NRG Oncology · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Stomatitis studies recruiting now, 21 (45%) set no upper age limit and 22 (47%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 60 across 276 interventional studies indexed under Stomatitis.
Median enrollment 60 across the 73 interventional studies, 22 across the 6 observational. Of the 60 that completed or were terminated, 26 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Stomatitis — fewer than ten, so there is no comparison to draw.
8 of the studies in Stomatitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07290413Brigham and Women's HospitalPhotobiomodulation for the Prevention of Oral Mucositis | 2026-12 |
| NCT04805320University of NebraskaAssociation of Periodontal Inflammation on Immune Response in Wound Healing | 2027-01 |
| NCT06532279NRG OncologyTesting the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | 2027-01-01 |
| NCT07287826Woman'sUsing a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy | 2027-07 |
| NCT05966194EpicentRx, Inc.RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Stomatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy
This was a Phase 2, placebo-controlled, double-blind study in subjects newly diagnosed with head and neck cancer (who had not received previous treatment for oral mucositis) and who were receiving concomitant chemotherapy and radiotherapy. Subject eligibility, including tumor staging, was assessed during the screening period, which was to occur within 30 days prior to the initiation of radiation therapy. The radiation therapy treatment period was approximately 7 weeks, depending on the subject's prescribed radiation plan. Prior to the randomized portion of the trial, the first 7 subjects enrolled in the study entered a safety run-in evaluation and received a total of 2 doses of open-label clazakizumab 160 mg IV, 4 weeks apart (Day 0 and Week 4 of radiation); these subjects were not eligible for the randomized portion of the study. Subsequent to completion of the safety run-in, eligible subjects were randomized 1:1:1 to treatment with 2 doses of clazakizumab 160 mg, or clazakizumab 320 mg, or placebo, administered IV 3 weeks apart (Day 0 and Week 3 of radiation therapy). All subjects were to be followed for 4 weeks post last day of radiotherapy treatment for the primary efficacy and safety assessments and then for up to an additional 12 months of long-term follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ALD518
Biological: ALD518
Biological: ALD518
Drug: 0.9% saline
IV
IV Infusion
Percent of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities
Time frame: Up to 15 months
Number of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Abnormalities
Time frame: Up to 15 months
Percent of Participants With All Grades of Oral Mucositis (OM) at a Radiation Dose of 55 Gy
Gray (Gy) is used as a unit of the radiation quantity absorbed dose that measures the energy deposited by ionizing radiation in a unit mass of matter being irradiated, and is used for measuring the delivered dose of ionizing radiation in applications such as radiotherapy. The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy
Time frame: Up to 12 weeks
Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy
The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy
Time frame: Up to 12 weeks
Percent of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)
The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
Time frame: Up to 12 weeks
Number of Participants With Ulcerative OM at Varying Cumulative Radiation Doses (Gy)
The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
Time frame: Up to 12 weeks
Percent of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)
The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
Time frame: Measured from onset of OM through Week 12
Number of Participants With Severe OM at Varying Cumulative Radiation Doses (Gy)
The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
Time frame: Up to 12 weeks
Duration of Ulcerative and Severe OM
Time frame: Up to 12 weeks
Time to Onset of Ulcerative and Severe OM
Time frame: Up to 12 weeks
ALD518 Plasma Concentration at Varying Weeks
Time frame: Baseline and up to 12 weeks
Oral Mucositis Daily Questionnaire (OMDQ) Overall Health Score at Varying Cumulative Radiation Doses (Gy)
Scored on a scale from 0 (worst possible overall health) to 10 (perfect overall health). Higher scores represent better overall health.
Time frame: Baseline and up to 12 weeks
Functional Assessment of Cancer Therapy - Head and Neck (FACT-HN) Questionnaire Overall Assessment Score at Varying Cumulative Radiation Doses (Gy)
The FACT-HN consists of 28 general + 11 head and neck specific items, each rated on a 0 (not at all) to 4 (very much) Likert type scale. The total score ranges from 0 to 148. Higher scores represent better quality of life.
Time frame: Baseline and up to 12 weeks
Functional Assessment of Chronic Illness Therapy - Fatigue Questionnaire (FACIT-F) Score at Varying Cumulative Radiation Doses (Gy)
The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale from 0 (not at all fatigued) to 4 (very much fatigued). The total score ranges from 0 to 52. Higher scores represent less fatigue.
Time frame: Baseline and up to 12 weeks
Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks
The level of C-reactive protein (CRP), which can be measured in your blood, increases when there's inflammation in your body.
Time frame: Baseline and up to 12 weeks
| Milestone | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Started | 24 | 7 | 23 | 22 |
| Completed | 23 | 7 | 19 | 19 |
| Not completed | 1 | 0 | 4 | 3 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 2 | 1 |
| percentage of participants | Placebo | ALD518 (160 mg) | ALD518 (320 mg) |
|---|---|---|---|
| Adverse events (AEs) | 95.7 | 100 | 100 |
| Serious adverse events | 30.4 | 46.9 | 38.1 |
| Clinically significant laboratory abnormalities | 0 | 6.3 | 4.8 |
| Treatment-related AEs | 52.2 | 65.6 | 57.1 |
| AEs leading to treatment discontinuation | 0 | 3.1 | 4.8 |
| participants | Placebo | ALD518 (160 mg) | ALD518 (320 mg) |
|---|---|---|---|
| Adverse events (AEs) | 22 | 32 | 21 |
| Serious adverse events | 7 | 15 | 8 |
| Clinically significant laboratory abnormalities | 0 | 2 | 1 |
| Treatment-related AEs | 12 | 21 | 12 |
| AEs leading to treatment discontinuation | 0 | 1 | 1 |
Gray (Gy) is used as a unit of the radiation quantity absorbed dose that measures the energy deposited by ionizing radiation in a unit mass of matter being irradiated, and is used for measuring the delivered dose of ionizing radiation in applications such as radiotherapy. The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy
| percentage of participants | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Percent of Participants With All Grades of Oral Mucositis (OM) at a Radiation Dose of 55 Gy | 79.2 | 71.4 | 100 | 77.3 |
The 55 Gy ulcerative OM assessment is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in their cumulative dose of radiation being ≥ 55 Gy
| participants | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy | 19 | 5 | 23 | 17 |
The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
| percentage of participants | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| 35 Gy | 58.3 | 85.7 | 81.8 | 65.0 |
| 45 Gy | 87.5 | 85.7 | 90.9 | 75.0 |
| 55 Gy | 79.2 | 71.4 | 100 | 75.0 |
| 65 Gy | 83.3 | 83.3 | 100 | 68.8 |
The ulcerative OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first ulcerative OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
| participants | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| 35 Gy | 14 | 6 | 18 | 13 |
| 45 Gy | 21 | 6 | 20 | 15 |
| 55 Gy | 19 | 5 | 22 | 15 |
| 65 Gy | 15 | 5 | 19 | 11 |
The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
| percentage of participants | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| 35 Gy | 25.0 | 57.1 | 27.3 | 30.0 |
| 45 Gy | 41.7 | 71.4 | 36.4 | 45.0 |
| 55 Gy | 50.0 | 71.4 | 40.9 | 55.0 |
| 65 Gy | 55.6 | 50.0 | 63.2 | 43.8 |
The severe OM assessment at a specific cumulative radiation dose (35 Gy, 45 Gy, 55 Gy or 65 Gy) is defined as the first severe OM assessment that occurred on the day of or after the subject received the radiation therapy that first resulted in the specific cumulative dose of radiation being ≥35 Gy, ≥45 Gy, ≥55 Gy or≥ 65 Gy
| participants | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| 35 Gy | 6 | 4 | 6 | 6 |
| 45 Gy | 10 | 5 | 8 | 9 |
| 55 Gy | 12 | 5 | 9 | 11 |
| 65 Gy | 10 | 3 | 12 | 7 |
| Days | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Ulcerative | 42.0 ± 23.17 | 55.1 ± 26.57 | 48.3 ± 16.71 | 38.0 ± 29.53 |
| Severe | 22.4 ± 23.28 | 35.1 ± 28.02 | 22.7 ± 18.95 | 21.5 ± 25.01 |
| Days | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Ulcerative | 23.7 ± 7.05 | 18.7 ± 5.32 | 22.9 ± 5.97 | 24.3 ± 13.37 |
| Severe | 37.0 ± 11.81 | 26.1 ± 5.72 | 43.1 ± 17.55 | 38.0 ± 15.64 |
| ug/mL | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|
| at Baseline | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| at Week 2 | 24.3 ± 9.98 | 20.6 ± 3.73 | 32.7 ± 5.24 |
| at Week 4 | 18.8 ± 6.62 | 40.6 ± 7.53 | 80.6 ± 20.21 |
| at Week 8 (last day of RT) | 31.6 ± 12.02 | 23.1 ± 6.64 | 46.9 ± 13.74 |
| at Week 12 (4 weeks post RT) | 16.8 ± 9.54 | 11.5 ± 3.10 | 20.6 ± 14.42 |
Scored on a scale from 0 (worst possible overall health) to 10 (perfect overall health). Higher scores represent better overall health.
| score on a scale | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Baseline | 6.5 ± 1.95 | 8.4 ± 1.40 | 7.2 ± 1.66 | 6.7 ± 2.35 |
| 35 Gy (up to 12 weeks) | 5.2 ± 2.08 | 6.6 ± 2.07 | 5.2 ± 2.05 | 5.5 ± 1.91 |
| 45 Gy (up to 12 weeks) | 5.6 ± 1.89 | 5.7 ± 2.14 | 5.4 ± 1.86 | 5.4 ± 2.40 |
| 55 Gy (up to 12 weeks) | 5.1 ± 1.96 | 5.9 ± 2.54 | 5.3 ± 2.22 | 5.1 ± 2.27 |
| 65 Gy (up to 12 weeks) | 5.6 ± 1.79 | 5.7 ± 3.08 | 5.3 ± 2.11 | 5.6 ± 2.37 |
The FACT-HN consists of 28 general + 11 head and neck specific items, each rated on a 0 (not at all) to 4 (very much) Likert type scale. The total score ranges from 0 to 148. Higher scores represent better quality of life.
| score on a scale | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Baseline | 116.5 ± 15.86 | 129.4 ± 12.63 | 113.8 ± 19.53 | 111.3 ± 20.94 |
| 35 Gy (up to 12 weeks) | 92.9 ± 20.14 | 100.3 ± 24.14 | 96.2 ± 21.18 | 92.2 ± 19.96 |
| 45 Gy (up to 12 weeks) | 90.6 ± 18.18 | 94.7 ± 30.14 | 89.7 ± 23.49 | 86.6 ± 21.34 |
| 55 Gy (up to 12 weeks) | 89.6 ± 19.36 | 82.3 ± 17.79 | 84.4 ± 25.67 | 81.1 ± 22.13 |
| 65 Gy (up to 12 weeks) | 85.2 ± 18.13 | 93.6 ± 27.50 | 86.5 ± 18.00 | 86.5 ± 23.95 |
The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale from 0 (not at all fatigued) to 4 (very much fatigued). The total score ranges from 0 to 52. Higher scores represent less fatigue.
| score on a scale | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) |
|---|---|---|---|---|
| Baseline | 42.5 ± 7.26 | 47.6 ± 3.26 | 42.6 ± 8.61 | 39.7 ± 10.94 |
| 35 Gy (up to 12 weeks) | 31.1 ± 12.56 | 30.1 ± 16.63 | 34.0 ± 9.59 | 31.2 ± 13.56 |
| 45 Gy (up to 12 weeks) | 30.3 ± 11.42 | 28.9 ± 15.61 | 31.2 ± 12.33 | 30.4 ± 11.65 |
| 55 Gy (up to 12 weeks) | 29.9 ± 12.95 | 20.8 ± 14.70 | 28.0 ± 12.95 | 26.8 ± 13.71 |
| 65 Gy (up to 12 weeks) | 29.6 ± 10.81 | 26.8 ± 18.71 | 27.3 ± 9.65 | 29.5 ± 12.40 |
The level of C-reactive protein (CRP), which can be measured in your blood, increases when there's inflammation in your body.
| mg/L | Placebo | ALD518 (160 mg) | ALD518 (320 mg) |
|---|---|---|---|
| Week 1 | 3.50 (3.5 to 3.5) | -2.20 (-2.4 to -2.1) | -1.15 (-1.7 to -0.6) |
| Week 2 | 8.39 (-13.1 to 73.1) | -6.52 (-31.8 to -0.1) | -14.74 (-75.6 to -0.2) |
| Week 3 | 12.35 (0.8 to 23.9) | -1.75 (-2.3 to -0.4) | -14.78 (-29.2 to -0.6) |
| Week 4 | 4.71 (-12.6 to 38.1) | -6.82 (-31.8 to -0.1) | -14.63 (-75.7 to -0.2) |
| Week 5 | 27.85 (8.6 to 47.1) | -15.50 (-42.2 to -1.9) | -6.30 (-27.7 to -0.6) |
| Week 6 | 20.52 (-9.5 to 98.2) | -6.93 (-31.8 to 0.7) | -11.92 (-75.7 to -0.9) |
| Week 8 (last day of RT) | 6.51 (-5.3 to 58.8) | -7.84 (-42.8 to -0.1) | -13.96 (-75.7 to -0.2) |
| Week 12 (4 weeks post RT) | 2.99 (-12.6 to 51.2) | -8.16 (-42.9 to -0.1) | -14.53 (-75.7 to -0.2) |
Collected over Up to 15 months for each participant. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/23 (0%) | 7/23 (30.4%) | 22/23 (95.7%) |
| ALD518 (160 mg) | 4/32 (12.5%) | 15/32 (46.9%) | 32/32 (100%) |
| ALD518 (320 mg) | 2/21 (9.5%) | 8/21 (38.1%) | 21/21 (100%) |
| Event | Placebo | ALD518 (160 mg) | ALD518 (320 mg) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/23 | 3/32 | 0/21 |
| General physical health deteriorationGeneral disorders | 1/23 | 3/32 | 0/21 |
| PyrexiaGeneral disorders | 2/23 | 0/32 | 0/21 |
| DehydrationMetabolism and nutrition disorders | 2/23 | 1/32 | 1/21 |
| Oral painGastrointestinal disorders | 1/23 | 2/32 | 0/21 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/23 | 0/32 | 1/21 |
| Acute myocardial infarctionCardiac disorders | 0/23 | 0/32 | 1/21 |
| Myocardial infarctionCardiac disorders | 0/23 | 0/32 | 1/21 |
| Tongue haemorrhageGastrointestinal disorders | 0/23 | 0/32 | 1/21 |
| Abscess limbInfections and infestations | 0/23 | 0/32 | 1/21 |
| Event | Placebo | ALD518 (160 mg) | ALD518 (320 mg) |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 13/23 | 22/32 | 9/21 |
| NauseaGastrointestinal disorders | 14/23 | 20/32 | 14/21 |
| Oral candidiasisInfections and infestations | 11/23 | 18/32 | 8/21 |
| Weight decreasedInvestigations | 7/23 | 11/32 | 11/21 |
| DysgeusiaNervous system disorders | 12/23 | 11/32 | 5/21 |
| VomitingGastrointestinal disorders | 9/23 | 12/32 | 10/21 |
| DiarrhoeaGastrointestinal disorders | 10/23 | 7/32 | 3/21 |
| Dry mouthGastrointestinal disorders | 10/23 | 11/32 | 5/21 |
| White blood cell count decreasedInvestigations | 2/23 | 3/32 | 9/21 |
| LeukopeniaBlood and lymphatic system disorders | 7/23 | 13/32 | 6/21 |
| Age, Continuous(years) | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) | Total |
|---|---|---|---|---|---|
| Mean | 58.8 ± 7.92 | 56.3 ± 11.93 | 58.6 ± 7.43 | 55.1 ± 7.18 | 57.4 ± 8.00 |
| Sex: Female, Male(Participants) | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) | Total |
|---|---|---|---|---|---|
| Female | 4 | 1 | 7 | 1 | 13 |
| Male | 20 | 6 | 16 | 21 | 63 |
| Region of Enrollment(participants) | Placebo | ALD518 (160 mg, OL) | ALD518 (160 mg, R) | ALD518 (320 mg, R) | Total |
|---|---|---|---|---|---|
| Canada | 0 | 0 | 0 | 1 | 1 |
| Austria | 0 | 0 | 1 | 4 | 5 |
| United States | 7 | 6 | 5 | 8 | 26 |
| Italy | 3 | 0 | 5 | 4 | 12 |
| Australia | 9 | 1 | 2 | 3 | 15 |
| Germany | 5 | 0 | 10 | 2 | 17 |
The record gives a start of Jul 2011, a primary completion of Apr 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 8 years 1 month after primary completion. A results delay was requested in Jun 2014.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clazakizumab